A citation-based method for searching scientific literature


List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.
Matthew J Page, Joanne E McKenzie, Patrick M Bossuyt, Isabelle Boutron, Tammy C Hoffmann, Cynthia D Mulrow, Larissa Shamseer, Jennifer M Tetzlaff, Elie A Akl, Sue E Brennan,[...]. PLoS Med 2021
334
100

Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model.
Guillaume Vial, Marie-Agnès Chauvin, Nadia Bendridi, Annie Durand, Emmanuelle Meugnier, Anne-Marie Madec, Nathalie Bernoud-Hubac, Jean-Paul Pais de Barros, Éric Fontaine, Cécile Acquaviva,[...]. Diabetes 2015
80
50


Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
Julie Dubourg, Sandrine Perrimond-Dauchy, Mathieu Felices, Sébastien Bolze, Pascal Voiriot, Pascale Fouqueray. Eur J Clin Pharmacol 2020
4
50


Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis.
Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar. J Diabetes Res 2020
13
50




The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Pascale Fouqueray, Valdis Pirags, Silvio E Inzucchi, Clifford J Bailey, Guntram Schernthaner, Michaela Diamant, Harold E Lebovitz. Diabetes Care 2013
46
50

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration.
D Detaille, G Vial, A-L Borel, C Cottet-Rouselle, S Hallakou-Bozec, S Bolze, P Fouqueray, E Fontaine. Cell Death Discov 2016
40
50

The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Pascale Fouqueray, Valdis Pirags, Michaela Diamant, Guntram Schernthaner, Harold E Lebovitz, Silvio E Inzucchi, Clifford J Bailey. Diabetes Care 2014
37
50

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.
Dídac Mauricio, Luigi Meneghini, Jochen Seufert, Laura Liao, Hongwei Wang, Liyue Tong, Anna Cali, Peter Stella, Paulo Carita, Kamlesh Khunti. Diabetes Obes Metab 2017
68
50

Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress.
Hiroki Kitakata, Jin Endo, Shun Hashimoto, Erika Mizuno, Hidenori Moriyama, Kohsuke Shirakawa, Shinichi Goto, Yoshinori Katsumata, Keiichi Fukuda, Motoaki Sano. Biochem Biophys Res Commun 2021
7
50


Efficacy of Alpha-lipoic Acid in The Management of Diabetes Mellitus: A Systematic Review and Meta-analysis.
Mahmoud Ahmed Ebada, Notila Fayed, Laila Fayed, Souad Alkanj, Ahmed Abdelkarim, Haya Farwati, Aya Hanafy, Ahmed Negida, Mohamed Ebada, Yousef Noser. Iran J Pharm Res 2019
8
50


Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Sophie Hallakou-Bozec, Guillaume Vial, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, Anne-Laure Borel, Eric Fontaine, David E Moller. Diabetes Obes Metab 2021
29
50

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Brendon L Neuen, Clare Arnott, Vlado Perkovic, Gemma Figtree, Dick de Zeeuw, Greg Fulcher, Min Jun, Meg J Jardine, Sophia Zoungas, Carol Pollock,[...]. Diabetes Obes Metab 2021
22
50


Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90).
Jose Leal, Maria Alva, Vanessa Gregory, Alison Hayes, Borislava Mihaylova, Alastair M Gray, Rury R Holman, Philip Clarke. Diabet Med 2021
2
50

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial.
Min Jun, Katie Harris, Hiddo J L Heerspink, Sunil V Badve, Meg J Jardine, Stephen Harrap, Pavel Hamet, Michel Marre, Neil Poulter, Sradha Kotwal,[...]. Diabetes Obes Metab 2021
2
50

A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences.
Thomas J Hoerger, John S Wittenborn, Joel E Segel, Nilka R Burrows, Kumiko Imai, Paul Eggers, Meda E Pavkov, Regina Jordan, Susan M Hailpern, Anton C Schoolwerth,[...]. Am J Kidney Dis 2010
65
50

Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016.
Yiling J Cheng, Alka M Kanaya, Maria Rosario G Araneta, Sharon H Saydah, Henry S Kahn, Edward W Gregg, Wilfred Y Fujimoto, Giuseppina Imperatore. JAMA 2019
173
50



Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
Amanda I Adler, Richard J Stevens, Sue E Manley, Rudy W Bilous, Carole A Cull, Rury R Holman. Kidney Int 2003
50

Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Catherine M Clase, Joshua Barzilay, Peggy Gao, Andrew Smyth, Roland E Schmieder, Sheldon Tobe, Koon K Teo, Salim Yusuf, Johannes F E Mann. Kidney Int 2017
46
50

Calibrating models in economic evaluation: a seven-step approach.
Tazio Vanni, Jonathan Karnon, Jason Madan, Richard G White, W John Edmunds, Anna M Foss, Rosa Legood. Pharmacoeconomics 2011
92
50


SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
332
50

The changing natural history of nephropathy in type I diabetes.
A S Krolewski, J H Warram, A R Christlieb, E J Busick, C R Kahn. Am J Med 1985
773
50

Trajectories of kidney function in diabetes: a clinicopathological update.
Megumi Oshima, Miho Shimizu, Masayuki Yamanouchi, Tadashi Toyama, Akinori Hara, Kengo Furuichi, Takashi Wada. Nat Rev Nephrol 2021
16
50


Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO).
Hui Shao, Vivian Fonseca, Charles Stoecker, Shuqian Liu, Lizheng Shi. Pharmacoeconomics 2018
37
50

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
341
50

Intensive BP Control and eGFR Declines: Are These Events Due to Hemodynamic Effects and Are Changes Reversible?
Debbie C Chen, Wendy McCallum, Mark J Sarnak, Elaine Ku. Curr Cardiol Rep 2020
2
50

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
50


New pharmacological strategies for protecting kidney function in type 2 diabetes.
Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink. Lancet Diabetes Endocrinol 2019
44
50

Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT.
Srinivasan Beddhu, Jincheng Shen, Alfred K Cheung, Paul L Kimmel, Glenn M Chertow, Guo Wei, Robert E Boucher, Michel Chonchol, Farid Arman, Ruth C Campbell,[...]. J Am Soc Nephrol 2019
28
50

Cost-of-illness study of type 2 diabetes mellitus in Colombia.
Juan Camilo González, John H Walker, Thomas R Einarson. Rev Panam Salud Publica 2009
20
50

Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
Hui Zhang, Chao Zhang, Sufen Zhu, Hongjian Ye, Donglan Zhang. BMC Health Serv Res 2020
4
50

An economic model of the long-term health care burden of Type II diabetes.
A Bagust, P K Hopkinson, W Maier, C J Currie. Diabetologia 2001
73
50

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.
Nobuya Inagaki, Wenying Yang, Hirotaka Watada, Linong Ji, Sven Schnaidt, Egon Pfarr, Tomoo Okamura, Odd Erik Johansen, Jyothis T George, Maximilian von Eynatten,[...]. Diabetol Int 2019
16
50

Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa, Japan.
Kunitoshi Iseki, Yoshiharu Ikemiya, Kozen Kinjo, Chiho Iseki, Shuichi Takishita. Clin Exp Nephrol 2004
18
50

Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents?
Ylenia Ingrasciotta, Janet Sultana, Dario Formica, Valentina Ientile, Andrea Aiello, Alessandro Chinellato, Daniele Ugo Tari, Rosa Gini, Maurizio Pastorello, Salvatore Scondotto,[...]. Pharmacoepidemiol Drug Saf 2021
3
50

A computer simulation model of diabetes progression, quality of life, and cost.
Honghong Zhou, Deanna J M Isaman, Shari Messinger, Morton B Brown, Ronald Klein, Michael Brandle, William H Herman. Diabetes Care 2005
79
50

Economic Simulation Modeling in Type 2 Diabetes.
Rahul S Dadwani, Neda Laiteerapong. Curr Diab Rep 2020
4
50

Chronic kidney disease.
Kamyar Kalantar-Zadeh, Tazeen H Jafar, Dorothea Nitsch, Brendon L Neuen, Vlado Perkovic. Lancet 2021
92
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.